ANESTHETIC PRODUCT PACT
Sweden's Kabi Pharmacia and Anaquest, a division of BOC Health Care Inc, have announced a major cooperative agreement concerning anesthetic products.
Under the terms of the new agreement, Kabi will have an option to market Anaquest's new anesthesia products in Europe. The deal covers new products developed over the next decade. Correspondingly, Anaquest will have an option to obtain North American marketing rights of Kabi's anesthetics.
The first product to be covered by the agreement is the new inhalation anesthetic Suprane (desflurane), which is currently undergoing review in a number of European countries. The first launches of the product are expected this fall. Kabi will become the sole European distributor for Suprane. This product is also being reviewed by the US Food and Drug Administration. The current inhalation anesthetic market in Europe is in excess of $125 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze